Both sorafenib and sunitinib are oral multikinase inhibitors that target tumor proliferation and angiogenesis by inhibiting VEGFRs, platelet-derived growth factor receptors (PDGFRs), FMS-like tyrosine kinase 3 (Flt-3), c-Kit protein, and RET receptor tyrosine kinases; however, they do not have identical kinase inhibition profiles [6–8]. Here, FLT3 is linked to neoplasm.